EGFR MUTATION ANALYSIS

Tellgen

EGFR MUTATION ANALYSIS-by Real-Time PCR Analysis

Features & Benefits

Detailed mutation genotypes

1 sample 1 reaction

Targeted Mutations

Mutation	Base change	Mutation	Base Change
G719C	2155G＞T	E746-S752>D	2238-2255del18
E746-A750del(1)	2235_2249del 15	L747-A750>P	2238-2248>GC (complex)
E746-A750del(2)	2236_2250del 15	L747-T751>Q	2238-2252>GCA (complex)
L747_T751＞S	2240_2251del 12	L747-T751del(1)	2239-2253del15
L747_P753＞S	2240_2257del 18	L747-S752del	2239-2256del18
L858R	2573T＞G	L747-A750P	2239-2248TTAAGAGAAG>C
L861Q	2582T＞A	L747-A750>P	2239-2248TTAAGAGAAG>C
T790M	2369C＞T	L747-T751>P	2239-2251>C (complex)
G719A	2156G>C		2230-2251del12
G719S	2155G>A	L747-T751del(2)	2240-2254del15
E746-A750>I	2235>2252>AAT (complex)	S768I	2303G>T
E746-A751>A	2237-2251del15	V769-D770insASV	2307-2308insGCCAGCGTG
E746-T751>A	2237-2251del15	D770-N771insG	2310-2311insGCT
E746-S752>A	2237-2250>T (complex)	H773-774insH	2319-2320insCAC
E746-S752>V	2237-2255>T (complex)		

Tellgen Corporation
Address： Building 1,No.115,Lane 572,Bibo road,Free Trade Area,Shanghai 210203, P.R.China
Tel: +86-21-50862711 Fax: +86-21-50270390
Web: www.tellgencorp.com E-mail: sales@tellgen.com

EGFR

MUTATION ANALYSIS

Tellgen

EGFR MUTATION ANALYSIS - by Real-Time PCR

Non small-cell lung cancer (NSCLC) patients with a mutation in the epidermal growth-factor receptor (EGFR) gene appear to be more likely to benefit from gefitinib than from conventional chemotherapy.

Research demonstrated that the mutation of EGFR gene has close relation with sensitivity of gefitinib, and patients with EGFR mutations have been reported to respond to selective anti-EGFR tyrosine kinase inhibitors. The sensitivity rate of patients with mutation in exon 18,19 and 20 is higher than 71.2%, however 1.1% without mutation in those exons; besides that, the T790M mutation in exon 20 has close relation with gefitinib resistance.

Tellgen's EGFR 29 Mutation Kit is designed to detect the 29 most common EGFR mutations by RT- PCR. The results of the EGFR Kit are intended to aid the clinician in identifying cancer patients who may benefit from anti-epidermal growth factor receptor (EGFR) therapy, such as gefitinib.

Methodology

By Real-Time PCR

Targeted Mutations

29 mutations in 8 tubes

- ◇ T790M
- ◇ L858R
- ◇ L861Q
- ◇ S768IG719S，G719A and G719C
- ◇ 3 insert mutation in exon 20
- ◇ 19 deletion mutation in exon 19

Specimen Requirements

- ◇ Formalin-fixed, paraffin-embedded tissue
- ◇ Fresh tissue sample
- ◇ Frozen biopsy
- ◇ DNA materials

Features & Benefits

Mutation detected: 29 genotypes

Turnaround time: < 2 hours

Sensitivity: ~1%